News

Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.

In a new study, decreased plasma EGR1 protein levels and patients with fibromyalgia had a statistically significant relationship.

Resilience of participants with fibromyalgia had a stronger protective association among participants with average null or mild pain than with moderate or severe pain.

Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.

Patients with juvenile onset fibromyalgia and joint hypermobility demonstrated poorer overall functioning compared with those without joint hypermobility.

A clinically significant percentage of patients with fibromyalgia in the immediate intervention group had greater improvements in quality of life compared with patients in the delayed cohort.

Fibromyalgia was 3 times more common among patients with rheumatoid arthritis and Long COVID.

As fibromyalgia impact increased, self-stigmatization scores increased proportionally.

Results demonstrated rumination induction after physical activity stunted patients’ recovery regarding discomfort and pain intensity compared with patients using a distraction method.

John Botson, MD, discusses his study examining real-world pegloticase plus immunomodulation co-therapy using data from an insurance claims database.

In a new study, patients with psoriasis had a 39.46% prevalence of being overweight and 37.41% prevalence of obesity—83.56% patients also dismissed the importance of having healthy balanced eating habits.

A new study suggests vitamin D2 supplementation on patients with psoriasis is superior to vitamin D3 supplementation, but there was no significant difference in heterogeneity.

At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.

In this research presented at ACR 2023, investigators looked at potential factors which could predict flare risk after urate-lowering therapy initiation.

The 2 groups—the active control group who received smartphone notifications about general health advice and the intervention group who receive notifications on adherence-targeted information—did not have significant differences in serum urate levels.

In a recent study, participants had highest gout flare rates when serum urate levels were > 10 mg/dL and the lowest gout flare when levels were < 3.9 mg/dL.

Approximately 10% of patients with gout had a concomitant diagnosis of venous thromboembolism among nearly 800,000 hospitalizations in the US.

This new data from ACR 2023 suggests that the guidelines on a healthy diet predominantly based on plants have been confirmed with regard to incident gout.

Receipt of RZV was not associated with an increased risk of incident gout among more than 1,000 adults ≥ 65 years of age who received at least 1 dose of the 2-dose vaccine regimen.

At the follow-up with a study sample of 16.7 million patients, 6.9% of gout patients had chronic opioid use (n = 28,948) while 3.8% of the non-gout patients did.

Lifestyle habits including vegetable consumption and exercise were associated with Gout Impact Scale score.

In this data shown at ACR 2023, the URAT1 inhibitor known as AR882 showed promising phase 2b data for patients with gout.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.

In this late-breaking research shown at ACR 2023, TLC599 injection led to benefits in patients with a single injection and further benefits with a second.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

This segment of Dr. Fakih’s interview featured a discussion on the implications of his team’s findings presented at ACR 2023.

This research into improving quality measures for lupus patients was presented at ACR 2023 and funded by the CDC.